ResultsIQ

ResultsIQ › Latest results › Vimta Labs Limited

Vimta Labs Limited Q2 FY27 results deck summary

NSE: VIMTALABS · BSE: 524394

Results deck of 30 Oct 2026, summarised by AI from the filing.

Vimta Labs' Q2 FY27 total income rose 9.9% YoY to ₹1,149 mn, with EBITDA of ₹408 mn at 35.5% margin and PAT of ₹206 mn.

Key takeaways

  1. No guidance The presentation gives no forward revenue, margin or capex guidance for FY27 or beyond.
  2. Sequential dip EBITDA fell to ₹408 mn in Q2 FY27 from ₹411 mn in Q1 FY27 and PAT to ₹206 mn from ₹210 mn.
  3. Overseas mix Clinical research draws 75% of revenues from overseas and pharma analytical 40%, the stated base for growth.
  4. Margin pressure Material and testing costs rose to ₹262 mn in Q2 FY27 from ₹226 mn in Q1 FY27, alongside a lower EBITDA margin.

Original filing on BSE

Vimta Labs Limited Q1 FY27 results

As filed: Revenue ₹109 cr (+11% year on year), EBITDA ₹37.3 cr (+13% year on year), PAT ₹21.0 cr (+11% year on year), EBITDA margin 34.2% (+54 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹109 cr (+16% year on year), EBITDA ₹39.4 cr (+23% year on year), PAT ₹21.1 cr (+17% year on year), EBITDA margin 36.0% (+199 bps). Score 50 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 199 bps year on year. Share price after the results: +6.6% in 30 days (Nifty 500: −2.9%).
  • Q3 FY26: Revenue ₹98.6 cr (+11% year on year), EBITDA ₹34.2 cr (+4% year on year), PAT ₹17.6 cr (−16% year on year), EBITDA margin 34.7% (−236 bps). Score 35 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 236 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹9.6 cr on a year ago, more than the ₹9.0 cr it added the year before. Share price after the results: −17.6% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹102 cr (+23% year on year), EBITDA ₹33.0 cr (+18% year on year), PAT ₹20.0 cr (+33% year on year), EBITDA margin 32.4% (−138 bps). Score 52 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 138 bps year on year. Revenue rose ₹19.0 cr on a year ago, more than the ₹11.0 cr it added the year before. Share price after the results: −10.4% in 30 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹98.0 cr (+23% year on year), EBITDA ₹33.0 cr (+43% year on year), PAT ₹19.0 cr (+58% year on year), EBITDA margin 33.7% (+492 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin rose 492 bps year on year. Share price after the results: +39.4% in 28 days (Nifty 500: −3.4%).
  • Q4 FY25: Revenue ₹94.0 cr (+21% year on year), EBITDA ₹32.0 cr (+28% year on year), PAT ₹18.0 cr (+50% year on year), EBITDA margin 34.0% (+199 bps). Score 65 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 199 bps year on year. Profit fell 14% from last quarter. Share price after the results: −4.5% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹90.0 cr (+10% year on year), EBITDA ₹34.0 cr (+48% year on year), PAT ₹22.0 cr (+120% year on year), EBITDA margin 37.8% (+973 bps). Score 70 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin rose 973 bps year on year.
  • Q2 FY25: Revenue ₹85.0 cr (+16% year on year), EBITDA ₹29.0 cr (+81% year on year), PAT ₹15.0 cr (+150% year on year), EBITDA margin 34.1% (+1,000 bps). Score 87 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Vimta Labs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.